# Semax + Selank

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/semax-selank/

## Quick answers

**What is Semax + Selank?**

A cognitive-anxiolytic nasal blend combining the nootropic Semax with the anxiolytic Selank for simultaneous cognitive enhancement and stress reduction. Semax (ACTH(4-7)-Pro-Gly-Pro) plus Selank (tuftsin analogue), typically as a nasal spray.

**What is in Semax + Selank?**

Semax + Selank typically combines Semax and Selank. Commercial products vary.

**How strong is the evidence for Semax + Selank?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Semax and Selank each have clinical studies from Russia, where both are approved.

**Is Semax + Selank FDA-approved?**

No. Semax + Selank is not an approved product; no regulator has reviewed the combination.

**Is Semax + Selank banned in sport?**

No. Semax + Selank is not on the World Anti-Doping Agency Prohibited List.

**How does Semax + Selank work?**

This blend combines complementary nootropic and anxiolytic mechanisms: Semax (ACTH 4-10 analog) upregulates BDNF/NGF expression and enhances dopaminergic and serotonergic neurotransmission for cognition, while Selank (tuftsin analog) allosterically potentiates GABA-A receptor activity and modulates serotonin metabolism for anxiolysis without sedation.

**What is known about the safety of Semax + Selank?**

Both components are individually approved in Russia with clinical safety records. No sedation, dependency, or withdrawal effects reported.

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** not on the Prohibited List
- **Peptide:** yes
- **Routes studied:** Intranasal, Subcutaneous
- **Components:** Semax, Selank

## Overview

A cognitive-anxiolytic nasal blend combining the nootropic Semax with the anxiolytic Selank for simultaneous cognitive enhancement and stress reduction.

## Mechanism

This blend combines complementary nootropic and anxiolytic mechanisms: Semax (ACTH 4-10 analog) upregulates BDNF/NGF expression and enhances dopaminergic and serotonergic neurotransmission for cognition, while Selank (tuftsin analog) allosterically potentiates GABA-A receptor activity and modulates serotonin metabolism for anxiolysis without sedation.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Enhanced focus and cognitive performance
- Reduced anxiety and stress response
- Increased BDNF and neurotrophic support
- Improved emotional regulation

## Safety & unknowns

Both components are individually approved in Russia with clinical safety records. No sedation, dependency, or withdrawal effects reported. Combination widely used in nootropic communities. Minimal side effects reported. Not FDA-approved in the US. Intranasal delivery is well-tolerated.

## Studies

- Gusev EI, Martynov MY, Kostenko EV, et al. (2018). *[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]*. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/29798983/
  Russian clinical study of the Semax component in 110 patients after ischemic stroke, reporting higher plasma BDNF and faster motor and functional recovery with Semax and early rehabilitation.
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). *[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]*. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/18454096/
  Comparative trial of the Selank component versus medazepam in 62 patients with generalized anxiety disorder or neurasthenia; both drugs had similar anxiolytic effects.

## Status sources

- [Semax in patients at different stages of ischemic stroke (2018)](https://pubmed.ncbi.nlm.nih.gov/29798983/)
- [Selank in generalized anxiety disorder and neurasthenia (2008)](https://pubmed.ncbi.nlm.nih.gov/18454096/)
- [WADA 2026 Prohibited List (neither component named)](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.